Johnson & Johnson (NYSE:JNJ) Stake Lifted by Ilmarinen Mutual Pension Insurance Co

Ilmarinen Mutual Pension Insurance Co boosted its position in Johnson & Johnson (NYSE:JNJ) by 41.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 356,600 shares of the company’s stock after purchasing an additional 105,000 shares during the period. Johnson & Johnson makes up about 0.4% of Ilmarinen Mutual Pension Insurance Co’s portfolio, making the stock its 24th largest holding. Ilmarinen Mutual Pension Insurance Co’s holdings in Johnson & Johnson were worth $51,571,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Oregon Pacific Wealth Management LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $949,000. Horan Securities Inc. raised its holdings in Johnson & Johnson by 1.3% during the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock worth $1,038,000 after buying an additional 90 shares during the period. Strategic Financial Concepts LLC boosted its holdings in shares of Johnson & Johnson by 57.9% in the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock worth $501,000 after buying an additional 1,271 shares during the period. Lord Abbett & CO. LLC purchased a new position in shares of Johnson & Johnson in the third quarter worth approximately $69,859,000. Finally, KPP Advisory Services LLC raised its holdings in shares of Johnson & Johnson by 4.7% during the fourth quarter. KPP Advisory Services LLC now owns 11,492 shares of the company’s stock valued at $1,662,000 after acquiring an additional 515 shares during the period. 69.55% of the stock is owned by institutional investors.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $153.03 on Friday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The stock’s fifty day moving average is $159.75 and its 200-day moving average is $155.91. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The stock has a market capitalization of $368.77 billion, a PE ratio of 23.01, a PEG ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company’s revenue was up 5.3% on a year-over-year basis. During the same period last year, the company earned $2.29 earnings per share. Equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Citigroup lowered their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Wells Fargo & Company decreased their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Stifel Nicolaus reduced their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Raymond James reduced their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Finally, Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $171.33.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.